An Open-Label Extension Study to Assess the Long-Term Safety And Efficacy Of Dupilumab In Patients =6 Months To <18 Years Of Age With Atopic Dermatitis
What is the goal of the study?
To learn more about this study, please email the study team member listed below.
Who can participate in the study?
Please contact the study team listed below to learn more.